Avivo has developed an enzymatic platform that converts various blood group antigens to the universal donor type, group O, facilitating compatibility for organ transplants and blood transfusions. This technology optimizes the use of donated blood and organs, allowing healthcare providers to prioritize patients based on medical urgency and reduce waste in the transplant process.
Funding
$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods of matching blood types and organs for transplants and transfusions can lead to waste and limit the availability of compatible blood and organs for patients in need. This can result in prioritization challenges for healthcare providers and potentially adverse outcomes for patients awaiting transplants or transfusions.
Solution
Avivo is developing an enzymatic platform designed to convert various blood group antigens into the universal donor type, group O. This technology aims to optimize the utilization of donated blood and organs by eliminating the blood-matching barrier. By enabling the conversion of blood and organs to a universal type, Avivo's platform allows healthcare providers to prioritize patients based on medical urgency rather than blood type compatibility. The ex vivo enzymatic treatment has shown promise in converting blood type A donor lungs into universal blood type lungs, potentially increasing the number of viable organs available for transplant.
Target Audience
The primary target audience includes healthcare providers, transplant centers, blood banks, and hospitals seeking to optimize resource allocation and improve patient outcomes in blood transfusions and organ transplantation.
Features
- Enzymatic conversion of blood group antigens to universal donor type O
- Optimization of donated blood supply to meet specific needs
- Increased matching opportunities for living donor organ transplants
- Ex vivo enzymatic treatment for converting blood type A donor lungs